Baxter InternationalWBO:BAX +4.49%56 EBITDA Margin % is 11.44% as of Mar. 2026, which is 34% below its 10-year median of 17.39. GuruFocus rates WBO:BAX with a GF Score™ of 56/100 and a GF Value™ of €28.97 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Baxter International ranks worse than 51.23% on this metric.
Baxter International (WBO:BAX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Baxter International EBITDA Margin % Related Terms
Baxter International EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Baxter International's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:BAX vs COO, ATR, RGEN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Baxter International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxter International EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Baxter International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxter International (WBO:BAX) has a EBITDA Margin % of 11.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Baxter International and its competitors. This is 34% below median its historical median of 17.39. According to the industry distribution chart, Baxter International ranks #418 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 51.2%.
Is Baxter International's EBITDA Margin % too high?
Baxter International's current EBITDA Margin % of 11.44% is 34% below median its 10-year median of 17.39. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Baxter International's value of 11.44% is 53% above this industry median. Based on the distribution chart, Baxter International ranks #418 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Baxter International has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Baxter International's EBITDA Margin % compare to COO and ATR?
According to the Medical Devices & Instruments industry distribution chart, Baxter International ranks #418 out of 816 companies for EBITDA Margin %. This places Baxter International in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Baxter International's value of 11.44% is 53% above this benchmark. While the company's 10-year median is 17.39 vs. the industry median of 7.48, Baxter International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Baxter International's current EBITDA Margin % of 11.44% is 53% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Baxter International and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baxter International's current EBITDA Margin % is 11.44%, which is 34% below median its own 10-year median of 17.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (WBO:BAX) is currently considered Possible Value Trap. The stock's GF Value™ is €28.97, compared to a current price of €18.38 — trading 36.6% below its estimated fair value. The current EBITDA Margin % is 11.44%, which is 34% below median its 10-year median of 17.39 and 53% above the Medical Devices & Instruments industry median of 7.48. Baxter International's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Baxter International (WBO:BAX), the current EBITDA Margin % is 11.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baxter International (WBO:BAX) Overvalued in 2026?
Based on GuruFocus' analysis, Baxter International stock appears to be undervalued.
The current stock price of €18.38 is trading 36.6% below its estimated GF Value™ of €28.97.
GuruFocus considers Baxter International to be Possible Value Trap.
Key valuation signals for WBO:BAX:
EBITDA Margin %: 11.44% (34% below median its 10-year median of 17.39)
GF Value™: €28.97 vs. price of €18.38 (36.6% below fair value)
Industry Position: 53% above the Medical Devices & Instruments median (#418 of 816)
No single metric tells the full story. See the WBO:BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
56GF Score
Get the complete analysis for WBO:BAX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BAX has been successfully added to your 
